Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Olaf Stüve1, Mariko Kita, Daniel Pelletier

  • 1Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSAID use is associated with lower dementia and Alzheimer's disease prevalence and slower cognitive decline: A retrospective longitudinal analysis of the NACC cohort.

medRxiv : the preprint server for health sciences·2026
Same author

Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation.

Neurology and therapy·2026
Same author

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort.

Frontiers in immunology·2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.

The Lancet. Neurology·2026
Same author

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Mitoxantrone is the first approved drug for secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). This article details its pharmacology and the design of an ongoing Phase 2 clinical trial.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Mitoxantrone (Novantrone) holds the distinction of being the first medication approved in Western Europe and North America for treating specific forms of multiple sclerosis.
  • It is indicated for secondary progressive multiple sclerosis (SPMS) and progressive relapsing multiple sclerosis (PRMS).

Purpose of the Study:

  • To outline the pharmacological properties of mitoxantrone.
  • To discuss its established role in managing SPMS.
  • To detail the rationale and design of a current multi-center, double-blind, randomized, placebo-controlled Phase 2 trial investigating mitoxantrone.

Main Methods:

  • The study employs a multi-center, double-blind, randomized, placebo-controlled design.
  • This methodology is characteristic of a Phase 2 clinical trial.

Related Experiment Videos

  • The trial is ongoing, focusing on evaluating mitoxantrone's efficacy and safety.

    • Main Results:

    • Results are not yet available as the Phase 2 trial is ongoing.
    • The article will provide a comprehensive overview of the study's methodology.

    Conclusions:

    • The article provides foundational information on mitoxantrone for SPMS and PRMS.
    • It highlights the ongoing research efforts to further understand its therapeutic potential through a rigorous clinical trial design.